ATE502037T1 - Pyrimidin-4-yl-3,4-dihydro-2h-pyrroloä1, 2aüpyrazin-1-on verbindungen - Google Patents
Pyrimidin-4-yl-3,4-dihydro-2h-pyrroloä1, 2aüpyrazin-1-on verbindungenInfo
- Publication number
- ATE502037T1 ATE502037T1 AT06794699T AT06794699T ATE502037T1 AT E502037 T1 ATE502037 T1 AT E502037T1 AT 06794699 T AT06794699 T AT 06794699T AT 06794699 T AT06794699 T AT 06794699T AT E502037 T1 ATE502037 T1 AT E502037T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- independently
- compounds
- aryl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0520958.0A GB0520958D0 (en) | 2005-10-14 | 2005-10-14 | Compound |
| PCT/GB2006/003748 WO2007042784A2 (en) | 2005-10-14 | 2006-10-09 | Pyrimidin-4-yl-3, 4-dihydr0-2h- pyrrolo [1, 2a] pyrazin-1-one compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE502037T1 true ATE502037T1 (de) | 2011-04-15 |
Family
ID=35451786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06794699T ATE502037T1 (de) | 2005-10-14 | 2006-10-09 | Pyrimidin-4-yl-3,4-dihydro-2h-pyrroloä1, 2aüpyrazin-1-on verbindungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8404692B2 (de) |
| EP (1) | EP1940846B9 (de) |
| JP (1) | JP5266054B2 (de) |
| CN (1) | CN101326188B (de) |
| AT (1) | ATE502037T1 (de) |
| AU (1) | AU2006301031A1 (de) |
| BR (1) | BRPI0620968A2 (de) |
| DE (1) | DE602006020755D1 (de) |
| GB (1) | GB0520958D0 (de) |
| IL (1) | IL190713A0 (de) |
| RU (1) | RU2008118894A (de) |
| WO (1) | WO2007042784A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010031816A1 (en) * | 2008-09-19 | 2010-03-25 | Nerviano Medical Sciences S.R.L. | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| EP2788350B1 (de) * | 2011-10-07 | 2017-12-06 | Nerviano Medical Sciences S.r.l. | 4-alkyl-substituierte 3,4-dihydropyrrolo[1,2-a]pyrazin-1-(2h)-on-derivate als kinaseinhibitoren |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法 |
| WO2016100166A1 (en) | 2014-12-15 | 2016-06-23 | Bristol-Myers Squibb Company | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| WO2016192064A1 (en) * | 2015-06-03 | 2016-12-08 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| CN107849046B (zh) * | 2015-06-03 | 2020-06-12 | 常州捷凯医药科技有限公司 | 作为erk抑制剂的杂环化合物 |
| WO2017080980A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| RS60155B1 (sr) * | 2015-11-09 | 2020-05-29 | Astrazeneca Ab | Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| EP4194450A4 (de) * | 2020-08-07 | 2024-10-30 | Pharmablock Sciences (Nanjing), Inc. | Cdk9-inhibitor und verwendung davon |
| AU2021358123A1 (en) * | 2020-10-05 | 2023-06-08 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| KR102651320B1 (ko) * | 2022-08-11 | 2024-03-28 | 환인제약 주식회사 | 신규한 헤테로아릴 치환 유도체 및 이를 포함하는 신경퇴행성 질환, 암, 및 염증성 질환의 예방 또는 치료용 조성물 |
| WO2024035194A1 (ko) * | 2022-08-11 | 2024-02-15 | 환인제약 주식회사 | 신규한 헤테로아릴 치환 유도체 및 이를 포함하는 신경퇴행성 질환, 암, 및 염증성 질환의 예방 또는 치료용 조성물 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751742T3 (de) | 1986-01-13 | 2002-11-21 | American Cyanamid Co., Wayne | 4,5,6-Substituierte 2-Pyrimidinamine |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| DE10004157A1 (de) * | 2000-02-01 | 2001-08-02 | Merckle Gmbh Chem Pharm Fabrik | 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie |
| EP1257546A1 (de) * | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitoren |
| EP1274705A1 (de) * | 2000-03-29 | 2003-01-15 | Cyclacel Limited | 2-substituierte 4-heteroaryl-pyrimidine und ihre verwendung zur behandlung von proliferativen erkrankungen |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| EP1423388B1 (de) | 2001-02-20 | 2008-12-03 | AstraZeneca AB | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
| GB0107901D0 (en) | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| WO2003029248A1 (en) | 2001-09-28 | 2003-04-10 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0226582D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| CN1747949A (zh) * | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| JP2007500178A (ja) | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| EP1648875A1 (de) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren |
| CA2542880A1 (en) | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
-
2005
- 2005-10-14 GB GBGB0520958.0A patent/GB0520958D0/en not_active Ceased
-
2006
- 2006-10-09 BR BRPI0620968-8A patent/BRPI0620968A2/pt not_active Application Discontinuation
- 2006-10-09 RU RU2008118894/04A patent/RU2008118894A/ru not_active Application Discontinuation
- 2006-10-09 CN CN2006800462199A patent/CN101326188B/zh not_active Expired - Fee Related
- 2006-10-09 JP JP2008535085A patent/JP5266054B2/ja not_active Expired - Fee Related
- 2006-10-09 WO PCT/GB2006/003748 patent/WO2007042784A2/en not_active Ceased
- 2006-10-09 EP EP06794699A patent/EP1940846B9/de not_active Not-in-force
- 2006-10-09 US US12/083,534 patent/US8404692B2/en not_active Expired - Fee Related
- 2006-10-09 AT AT06794699T patent/ATE502037T1/de active
- 2006-10-09 AU AU2006301031A patent/AU2006301031A1/en not_active Abandoned
- 2006-10-09 DE DE602006020755T patent/DE602006020755D1/de active Active
-
2008
- 2008-04-08 IL IL190713A patent/IL190713A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006301031A8 (en) | 2008-05-08 |
| GB0520958D0 (en) | 2005-11-23 |
| WO2007042784A2 (en) | 2007-04-19 |
| CN101326188A (zh) | 2008-12-17 |
| JP5266054B2 (ja) | 2013-08-21 |
| US8404692B2 (en) | 2013-03-26 |
| DE602006020755D1 (de) | 2011-04-28 |
| CN101326188B (zh) | 2013-04-24 |
| WO2007042784A3 (en) | 2007-06-28 |
| US20100035870A1 (en) | 2010-02-11 |
| JP2009511555A (ja) | 2009-03-19 |
| IL190713A0 (en) | 2008-11-03 |
| EP1940846B9 (de) | 2012-09-12 |
| AU2006301031A1 (en) | 2007-04-19 |
| RU2008118894A (ru) | 2009-11-20 |
| BRPI0620968A2 (pt) | 2011-11-29 |
| EP1940846B1 (de) | 2011-03-16 |
| EP1940846A2 (de) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190713A0 (en) | Pyrimidin-4-yl-3,4-dihydro-2h-pyrrol0[1,2a] | |
| HRP20241482T1 (hr) | Kratki peptidni spoj prolina s modificiranim prstenom i njegova uporaba | |
| IL160769A (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| HUP0401783A2 (hu) | 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| DE60311995D1 (de) | Neue purine derivate | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| DE60228406D1 (de) | PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS | |
| DE60144392D1 (de) | Antivirale mittel | |
| ATE526341T1 (de) | Makrozyklische verbindungen als antivirale mittel | |
| EP1389463A4 (de) | Medikament zum inhibieren einer pumpe, mit der arzneimittel eliminiert werden | |
| DE602004031722D1 (de) | Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden | |
| HRP20020264B1 (hr) | 2'-supstituirani 1,1'-bifenil-2-karbonamidi, postupci za njihovu proizvodnju, njihova upotreba kao lijeka, kao i farmaceutski pripravci koji ih sadrže | |
| TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
| DE602005027213D1 (de) | Neue imidazolidinderivate | |
| SE0201937D0 (sv) | Therapeutic agents | |
| ATE254120T1 (de) | Neue verbindungen | |
| WO2007147770A3 (en) | Substituted phenyl methanone derivatives | |
| CA2262997A1 (en) | Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
| NO20005807D0 (no) | Nye kamptotekinanaloge forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| DE602004012388D1 (de) | Benzoxazolderivate und deren verwendung als adenosinrezeptorliganden | |
| SE9904177D0 (sv) | Novel compounds | |
| MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
| EA200600551A1 (ru) | Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат | |
| ATE195936T1 (de) | Bis-imide derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1940846 Country of ref document: EP |